FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

733464008: Ocrelizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2017. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3499483013 Ocrelizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3499484019 Ocrelizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
50661000195118 ocrelizumab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
828991000172114 ocrélizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
64711000195111 Ocrelizumab de Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Ocrelizumab Is a Monoclonal antibody true Inferred relationship Some
Ocrelizumab Is a Immunomodulator true Inferred relationship Some
Ocrelizumab This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. A substance that modifies the immune response or the functioning of the immune system. true Inferred relationship Some
Ocrelizumab Is a Immunologic agent (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing ocrelizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Ocrelizumab Inferred relationship Some 1
Ocrelizumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Ocrelizumab Inferred relationship Some 1
Ocrelizumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Ocrelizumab Inferred relationship Some 1
Ocrelizumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Ocrelizumab Inferred relationship Some 1
Ocrelizumab therapy (procedure) Direct substance True Ocrelizumab Inferred relationship Some 1

This concept is not in any reference sets

Back to Start